http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 발행기관 : John WileySons Australia, Ltd (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Park, Eun‐,Ock,Oh, Mi‐,Ra,Choi, Eun‐,Kyung,Shin, Dong‐,Hwa,Doo, Jae‐,Kyun,Kim, Young‐,Soo,Park, Young‐,Min,Jung, Eun‐,Soo,Park, Byung‐,Hyun,Chae, John WileySons Australia, Ltd 2016 Nutrition & dietetics Vol.73 No.2
<P>Aim: Mixed grain, which contributes to lowered glycaemic responses, has been shown to be effective in dietary management of patients with impaired glucose tolerance or diabetes. Methods: The present study determined the postprandial blood glucose response of 20 healthy volunteers to mixed grains containing giant embryonic rice (MG-GER) or giant embryonic brown rice (MG-GEBR) compared with white rice (WR) in a randomised crossover design. Plasma glucose and serum insulin at 0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes were measured, and glycaemic index (GI) and incremental area under the curve (iAUC) were calculated. Results: The GIs for WR, MG-GER and MG-GEBR were 86.75 5.78, 76.09 +/- 7.01 and 69.33 +/- 6.54, respectively. The 120-minute iAUCs after administration of MG-GER or MG-GEBR were significantly lower than that of WR. In addition, the MG-GEBR diet group had a significantly lower C-peptide concentration at the 120-minute time point when compared to the WR group. Conclusions: These results suggest that consumption of MG-GER or MG-GEBR instead of WR is more effective to reduce postprandial glucose levels without increasing insulin secretion.</P>
-
Lee, Won Kee,Lee, Shin Yup,Choi, Jin Eun,Seok, Yangki,Lee, Eung Bae,Lee, Hyun Cheol,Kang, Hyo‐,Gyoung,Yoo, Seung Soo,Lee, Myung Hoon,Cho, Sukki,Jheon, Sanghoon,Kim, Young Chul,Oh, In Jae,Na, Koo John WileySons Australia, Ltd 2017 Thoracic cancer Vol.8 No.3
<P><B>Background</B></P><P>This multicenter study was performed to develop a prognosis‐prediction model incorporating genetic polymorphism with pathologic stage for surgically treated non‐small cell lung cancer (NSCLC) patients.</P><P><B>Methods</B></P><P>A replication study including 720 patients and a panel of eight single nucleotide polymorphisms (SNPs), which predicted the prognosis of surgically treated NSCLC in our previous study, was conducted. Using the combined cohort of current and previous studies including 1534 patients, a nomogram for predicting overall survival was made using Cox proportional hazards regression.</P><P><B>Results</B></P><P>Among the eight SNPs, C3 rs2287845, GNB2L1 (alias RACK1), and rs3756585 were significantly associated with overall survival. A nomogram was constructed based on pathologic stage and the genotypes of the two SNPs, and the risk score was calculated for each patient in the combined cohort. Using the prognosis‐prediction model, we categorized patients into low, intermediate, and high‐risk groups, which had greater accuracy in predictive ability (log‐rank statistics = 54.66) than the conventional tumor node metastasis staging (log‐rank statistics = 39.56). Next, we generated a prognosis‐prediction model for stage I to identify a subgroup of potential candidates for adjuvant chemotherapy. Notably, 97 out of 499 stage IB patients were classified as high‐risk patients with a similar prognosis to stage II patients, suggesting the benefit of adjuvant chemotherapy.</P><P><B>Conclusions</B></P><P>This prognosis‐prediction model incorporating genetic polymorphism with pathologic stage may lead to more precise prognostication in surgically resected NSCLC patients. In particular, this model may be useful in selecting a subgroup of stage IB patients who may benefit from adjuvant chemotherapy.</P>
-
Kang, Da Hyun,Chung, Chaeuk,Kim, Ju‐,Ock,Jung, Sung Soo,Park, Hee Sun,Park, Dong Il,Jung, Sun Young,Park, Myoungrin,Lee, Jeong Eun John WileySons Australia, Ltd 2018 Thoracic cancer Vol.9 No.11
<P><B>Background</B></P><P>Immunotherapy is a new paradigm for the treatment of non‐small‐cell lung cancer (NSCLC), and targeting the PD‐1 or PD‐L1 pathway is a promising therapeutic option. Although PD‐1/PD‐L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because of hyperprogression and pseudoprogression. The aim of this study was to investigate the factors associated with tumor response and serious outcomes.</P><P><B>Methods</B></P><P>We retrospectively collected the medical records of 51 patients with advanced NSCLC who received PD‐1/PD‐L1 inhibitors between January 2016 and February 2018.</P><P><B>Results</B></P><P>The mean patient age was 63.9 years, and 72.5% (37/51) were male. Most (92.2%, 47/51) had received previous systemic treatment. The overall response rate was 21.6% (11/51). The response rate was significantly lower in patients with pleural or pericardial metastasis than in patients without pleural or pericardial metastasis (4.3% vs. 35.7%; <I>P</I> = 0.007). Patients with pleural or pericardial metastasis had a significantly higher rate of adverse events of any grade (91.3% vs. 50.0%; <I>P</I> = 0.002) and grade 3–5 adverse events (52.2% vs. 25.0%; <I>P</I> = 0.046).</P><P><B>Conclusion</B></P><P>Pleural or pericardial metastasis is a significant factor affecting the efficacy and rate of adverse events in advanced NSCLC patients treated with PD‐1/PD‐L1 inhibitors. Clinicians should pay attention to the use of immune checkpoint inhibitors in lung cancer patients with pleural or pericardial metastasis.</P>
-
Cho, Hwa Jin,Lee, Ji Hyeon,Lee, Geon Kook,Hong, Eun Kyung,Kim, Hyae Young John WileySons Australia, Ltd 2017 Thoracic cancer Vol.8 No.4
<P>We report the first case of a 62‐year‐old man with a sclerosing pneumocytoma (SP) combined with a typical carcinoid (TC) and pulmonary adenocarcinoma in different lung lobes. Computed tomography revealed two nodules. The radiological diagnosis was primary lung cancer and a metastatic nodule; however, no enlarged lymph nodes were observed. Histological and immunohistochemical analyses defined the 1.7 cm nodule in the right upper lobe as adenocarcinoma and the 1.3 cm nodule in the left lower lobe as SP combined with TC. This case is noteworthy because of the rarity of SP combined with TC, the comprehensive examination of frozen and permanent sections, and the clinical implications of the differential diagnosis of lung nodules.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
